All GSK articles
-
BusinessRevolutionising RSV prevention
New vaccines and a long-acting antibody aim to protect older adults and babies from respiratory syncytial virus
-
BusinessHaleon emerges from GSK consumer healthcare spin-off
Split illustrates move towards narrower focus in pharmaceuticals
-
BusinessSoapbark branches out to fill essential role in vaccine recipes
The soapbark tree has long been used in traditional medicines, but is now coveted for some of our newest vaccines
-
BusinessGSK accuses former employee of trade secret theft
Denise Brooks allegedly stole information about company’s manufacturing and quality systems
-
BusinessPharmaceuticals roundup 2021
It’s been another dramatic, pandemic-dominated year for the pharmaceutical industry
-
BusinessUS judge rules against GSK in trade secrets dispute
Firm will not receive compensation for claimed loses of over $1bn from theft of confidential information by two former scientists
-
OpinionA rough guide to pharma partnership deals
Coronavirus vaccines are driving unusual collaborations with a range of benefits
-
BusinessPharmaceuticals roundup 2019
Under the shadow of political turmoil and major lawsuits, the industry returned to its strengths – making new drugs, and finding new ways to do it better
-
BusinessNitrosamine contamination withdrawals spread to new drugs
After ranitidine recalls, EU regulators instruct companies to review all their products for potential impurities
-
NewsPilot malaria vaccination programme begins in Malawi
Mosquirix vaccine will be rolled out in Ghana and Kenya next week
-
BusinessGSK and Pfizer joint venture creates new consumer healthcare giant
Enlarged GSK consumer health will have largest market share of any firm and be a leader in key countries
-
BusinessPharmaceuticals roundup 2018
Merger deals, product approvals and infrastructure changes have been overshadowed by political uncertainty, in Europe and around the world
-
BusinessCleaning up clinical trials
Campaigns to enforce complete and correct reporting of trial data are beginning to take hold
-
BusinessNovartis to cut over 2000 jobs
Move exemplifies a wave of manufacturing cuts as pharma moves to more high-value, specialised medicines
-
BusinessGene therapy gathers pace
Sarah Houlton charts the evolution, challenges and opportunities of cell and gene therapy
-
NewsPatrick Vallance named as UK’s next chief scientific adviser
GlaxoSmithKline’s head of R&D will take up new post in March 2018
-
BusinessGSK’s shingles vaccine gets thumbs up in North America
Inoculation slated to be a blockbuster
-
BusinessUS to invest $160m in cancer partnership
Funds will be backed up with $55m from 11 companies to advance new cancer treatments that harness the immune system
-
-
BusinessGSK stops over 30 research programmes to prioritise innovation
New boss Emma Walmsley outlines sweeping changes in order to focus on high-return drug projects